Studies in animals show GLP-1 receptor agonists can reduce alcohol intake by over 50% in rats 23
Accessibility and Convenience: Evaluate how easy it is to schedule consultations, access prescriptions, and communicate with medical professionals
Retatrutide, developed under the code LY3437943, is a synthetic single-chain peptide engineered to act as an agonist at three receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR)
Approximately 82 to 88% of trial participants completed the study without discontinuing due to side effects
Why Retailers Love PatchAid: High-demand wellness product ideal for impulse and repeat purchases
The headline result was a mean 17.5% body-weight reduction at 24 weeks in the 12 mg arm, with clear dose-response behavior across the four active doses